This includes extended RAS testing (KRAS and NRAS exons 2,3,4) in advanced colorectal cancer (CRC) patients, which functions as well-established predictive biomarker for resistance to EGFR-targeted therapy (e.g. cetuximab or panitumumab) [1–5]. Here, KRAS is linked to colorectal carcinoma.